Literature DB >> 21414404

New method to produce equine antirabies immunoglobulin F(ab')₂ fragments from crude plasma in high quality and yield.

Sukanda Kittipongwarakarn1, Andrea Hawe, Ruedeeporn Tantipolphan, Kornvika Limsuwun, Sumana Khomvilai, Satit Puttipipatkhachorn, Wim Jiskoot.   

Abstract

Rabies is still a major cause of human deaths in several developing countries. According to the World Health Organization, administration of antirabies serum or antirabies immunoglobulin is recommended for patients who have experienced a category-III exposure to rabies. Improvement of antirabies immunoglobulin production is required to enhance safety and efficacy of the products. In this paper, a new method to produce equine antirabies immunoglobulin F(ab')(2) fragments from crude plasma is proposed. First, protein G affinity chromatography was used to purify IgG from equine plasma. Moreover, purification of IgG was shown to facilitate its digestion by pepsin. Compared to the direct digestion of crude plasma, a lower amount of pepsin and a shorter digestion time were required to completely digest the purified IgG to F(ab')(2). Complete digestion of purified IgG to F(ab')(2) was achieved at a pepsin/IgG (w/w) ratio of 5:45 with preservation of structure and potency. Finally, purification of F(ab')(2) was accomplished by a combination of protein A affinity chromatography and ultrafiltration with a 50-kDa nominal molecular weight cut-off membrane. The new process resulted in 68.9±0.6 (%) total recovery of F(ab')(2) and a F(ab')(2) product of high potency.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21414404     DOI: 10.1016/j.ejpb.2011.02.018

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  7 in total

1.  Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E.

Authors:  Dan-Yang Shi; Fu-Jia Liu; Yun-Yun Mao; Rong-Tian Cui; Jian-Sheng Lu; Yun-Zhou Yu; Xiao-Jie Dong; Zhi-Xin Yang; Zhi-Wei Sun; Xiao-Bin Pang
Journal:  Hum Vaccin Immunother       Date:  2019-07-26       Impact factor: 3.452

2.  Streamlined downstream process for efficient and sustainable (Fab')2 antivenom preparation.

Authors:  Tihana Kurtović; Marija Brgles; Maja Lang Balija; Stephanie Steinberger; Dora Sviben; Martina Marchetti-Deschmann; Beata Halassy
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2020-07-27

3.  Positron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab')(2) antibody fragment.

Authors:  Hao Hong; Yin Zhang; Hakan Orbay; Hector F Valdovinos; Tapas R Nayak; Jero Bean; Charles P Theuer; Todd E Barnhart; Weibo Cai
Journal:  Mol Pharm       Date:  2013-01-14       Impact factor: 4.939

4.  Prophylactic Efficacy of Equine Immunoglobulin F(ab')2 Fragments Against Feline Parvovirus.

Authors:  Jinfeng Liu; Zhenjiang Zhang; Anbin Bai; Yiyu Sha; Ling Ma; Shaomin Qin; Fenglian Chen; Shuying Qin; Jianmin Wu
Journal:  Appl Biochem Biotechnol       Date:  2021-06-04       Impact factor: 2.926

5.  An immunosensor based on antibody binding fragments attached to gold nanoparticles for the detection of peptides derived from avian influenza hemagglutinin H5.

Authors:  Urszula Jarocka; Róża Sawicka; Anna Góra-Sochacka; Agnieszka Sirko; Włodzimierz Zagórski-Ostoja; Jerzy Radecki; Hanna Radecka
Journal:  Sensors (Basel)       Date:  2014-08-25       Impact factor: 3.576

6.  Refinement strategy for antivenom preparation of high yield and quality.

Authors:  Tihana Kurtović; Maja Lang Balija; Marija Brgles; Dora Sviben; Monika Tunjić; Hrvoje Cajner; Martina Marchetti-Deschmann; Günter Allmaier; Beata Halassy
Journal:  PLoS Negl Trop Dis       Date:  2019-06-17

7.  Quality-Related Properties of Equine Immunoglobulins Purified by Different Approaches.

Authors:  Sanja Mateljak Lukačević; Tihana Kurtović; Maja Lang Balija; Marija Brgles; Stephanie Steinberger; Martina Marchetti-Deschmann; Beata Halassy
Journal:  Toxins (Basel)       Date:  2020-12-14       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.